UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

               Date of Report (Date of earliest event reported):
                                October 31, 2003

                              ENHANCE BIOTECH, INC.

               (Exact name of issuer as specified in its charter)

                                    Delaware
                 (State or other jurisdiction of incorporation)

           000-31653                                     95-4766094
   (Commission File Number)                  (IRS Employer Identification No.)

                666 Third Avenue, 16th Floor, New York, NY, 10017
              (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (212) 561-1716

        35th Floor, 1285 Avenue of the Americas New York, New York 10019
          (Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

Enhance  Biotech,  Inc. issued a press release on November 3, 2003 regarding the
closing of a private equity financing of $2.0 million through the sale of Common
Stock and warrants,  a copy of which is attached as Exhibit  10.21  hereto.  The
press release is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(a)      and (b) Not Applicable

(c)      Exhibits. The following exhibits are filed with this report:


         10.20    Form of  Securities  Purchase  Agreement by and among  Enhance
                  Biotech, Inc. and certain purchasers,  dated as of October 31,
                  2003

         10.21    Press  Release,  dated  November 3, 2003, of Enhance  Biotech,
                  Inc.



                         [Signature on following page.]



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                AUTO DATA NETWORK, INC.

                                By: /s/ Christopher Every
                                    ---------------------------------
                                    Christopher Every
                                    Chief Executive Officer


Date: November 4, 2002

                                  EXHIBIT INDEX

Exhibit  Description
- -------  -----------

10.20    Form of Securities  Purchase  Agreement by and among Enhance Biotech,
         Inc. and certain purchasers, dated as of October 31, 2003

10.21    Press Release, dated November 3, 2003, of Enhance Biotech, Inc.